BLTE · Belite Bio, Inc
$173.47
-0.91% last session
End-of-day data · close of 2026-09-11
Market cap
$7B
Enterprise value
—
Trailing P/E
—
Forward P/E
91.0
Dividend yield
—
Beta
-1.24
Avg volume
0M
Employees
0K
Daily Change %
-0.91%
5 Days Change
-5.40%
10 Days Change
17.63%
30 Days Change
3.14%
60 Days Change
22.65%
Month to Day Change
16.89%
Year to Day Change
14.50%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — BLTE
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-09
Latest call per bank · past 12 months
Morgan Stanley
Overweight$206
+17.7% vs priceBank of America
Buy$195
+11.4% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-09 | Mizuho | Maintains | Outperform | $220 → $234 |
| 2026-09-08 | HC Wainwright & Co. | Maintains | Buy | $214 → $245 |
| 2026-09-04 | Canaccord Genuity | Initiates | Buy | $0.00 → $303 |
| 2026-08-14 | Morgan Stanley | Maintains | Overweight | $201 → $206 |
| 2026-08-14 | Cantor Fitzgerald | Maintains | Overweight | $266 → $270 |
| 2026-08-12 | HC Wainwright & Co. | Maintains | Buy | $200 → $214 |
| 2026-06-15 | HC Wainwright & Co. | Reiterates | Buy | $200 |
| 2026-05-26 | Mizuho | Maintains | Outperform | $223 → $215 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 55 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 7.9% above the 50-day MA ($160.72).
- Price vs 200-day MA: Trading 9.0% above the 200-day MA ($159.14).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is positive (+1.54) — short-term momentum is improving.
- 52-week range: Price sits between the 52-week low ($66.80) and high ($193.61).
BLTE Price Chart
Loading chart for BLTE…
Fundamentals
About Belite Bio, Inc
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.